Poseida Therapeutics, Inc. (PSTX)

Poseida Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-60.76	-123.43	-64	-124.97	-129.78	-86.53
Depreciation & Amortization	5.48	5.61	5.17	4.55	2.59	1.19
Other Amortization	0.99	0.81	0.84	0.64	0.81	1.71
Loss (Gain) From Sale of Assets	0	0	0.35	-0	-	0.45
Loss (Gain) From Sale of Investments	-7.62	-8.39	-1.78	0.13	-0.17	-0.13
Stock-Based Compensation	23.03	23.13	18.93	16.7	7.22	3.05
Other Operating Activities	-	-3.99	-	-19.76	0.39	6.27
Change in Accounts Receivable	-6.08	0.08	-9.09	-	-	-
Change in Accounts Payable	2.67	1.04	-6.75	7.84	-4.17	1.53
Change in Unearned Revenue	22.08	6.73	27.3	13.76	-	-
Change in Other Net Operating Assets	5.18	6.23	2.26	-1.44	9.79	7.94
Operating Cash Flow	-15.02	-92.17	-26.77	-102.54	-113.33	-64.52
Capital Expenditures	-2.1	-3.07	-3.92	-2.63	-16.91	-5.16
Sale of Property, Plant & Equipment	-	-	0.01	0.02	-	-
Investment in Securities	40.26	42.2	-199.42	225	-187.52	-37.31
Investing Cash Flow	38.16	39.13	-203.33	222.38	-204.43	-42.46
Long-Term Debt Issued	-	-	30	-	-	10
Net Debt Issued (Repaid)	-	-	30	-	-	10
Issuance of Common Stock	1.29	16.62	76.61	2.52	223.98	0.07
Repurchase of Common Stock	-0.59	-0.49	-	-	-	-
Other Financing Activities	-	-	-1.45	-	-19.54	4.3
Financing Cash Flow	0.7	16.13	105.16	2.52	313.94	164.37
Net Cash Flow	23.84	-36.91	-124.95	122.36	-3.82	57.39
Free Cash Flow	-17.13	-95.23	-30.7	-105.18	-130.24	-69.67
Free Cash Flow Margin	-11.35%	-147.18%	-23.52%	-336.70%	-	-
Free Cash Flow Per Share	-0.18	-1.06	-0.43	-1.69	-3.62	-5.52
Cash Interest Paid	8.09	7.8	5.14	2.72	3.03	2.63
Levered Free Cash Flow	-22.24	-40.72	-17.93	-62.14	-84.2	-44.49
Unlevered Free Cash Flow	-17.56	-36.11	-14.79	-60.68	-82.82	-43.98

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q